Doclogic, I'm not a fan of optune but a few of the authors on the JAMA paper also speak of some benefits they have seen with the device. On the point of investors making a $ or two, if traded well nvcr was very rewarding. I sold my nvcr at 20 and 25 to purchase more nwbo - nvcr went to over $200 per share before the collapse